Dispersible tablets represent a dosage form combining two drugs in a ready-to-use tablet form that readily disperses into a suitable liquid before administration. The development of a dispersible combination tablet requires consideration of active ingredient distribution, excipient compatibility, dispersion properties, tablet strength and stability. If you are a pharma company with a targeting the expansion of your pediatric or specialist oral dosage offerings, this combination can also be incorporated as part of a structured PCD Pharma Franchise range.
Dispersion based combination formulation using levocetirizine dihydrochloride 2.5mg and montelukast 5mg Active Ingredient Combination Development involves analysis of potential incompatibilities, physical and chemical attributes of the active ingredients with the choice of excipients, testing of dispersion characteristics, and the resulting product strength and stability.
For pharma companies looking to grow their pediatric or specialty oral dosage product offering, this formulation has potential for inclusion in a structured PCD Pharma Franchise product portfolio.
Comparison of the physical and chemical characteristics of the drug and active ingredients – including dissolution and physical stability Essential quality parameters – in order to establish the standard active-ingredient distribution batch and plan for commercial batch production. Formulation design Diluents can be used to give the appropriate weight and improve processing properties. Super disintegrants are especially relevant for dispersible tablets as they support rapid separation of the tablet when added to a suitable liquid medium.
Binders can be used if needed to help ensure the appropriate strength of the finished tablet.
Suitable lubricants and glidants may help optimize production efficiency. Flavoring and sweetening agents may be incorporated into the formulation. Development of the pre formulation may involve investigations into flow properties, moisture sensitivity, compressibility, and compatibility of ingredients.
The active ingredients and excipients are blended in accordance with the approved manufacturing process and parameters in order to give a homogeneous distribution of the active ingredients within the final formulation. The active ingredients may be incorporated at separate strengths and the blending optimized through dilution and mixing to ensure consistent blending. The resulting blend can be tested for uniformity of composition according to approved specifications.
Depending on the process selected, the blend can then be compressed or subjected to a suitable granulation process.
Critical elements to be monitored at the granulation step include the granule size, flow, and moisture content. Formulation development can also include evaluation of flow properties, friability, cohesion, and compatibility of components. Compression of the granulate can be optimized for the best balance of strength and dispersion properties. The compression process can be subject to monitoring of tablet weight, thickness, hardness, and appearance.
The finished product can also be tested to ensure the ability of the final tablet to disperse according to the specification. Friability testing may also be performed, and visual inspection for cracks, surface flaws, laminations, chips or other defects can be undertaken. The tablet compression process can be optimized to give a product that is durable yet capable of dispersing quickly when immersed in the appropriate liquid medium.
Analytical quality control of finished dosage, physical parameters, dispersibility, and stability, in addition to maintaining the approved formulation with secure moisture protection, can offer an organized approach to product development in this high-demand area. PCD Pharma Franchise combination dispersible formulation including levocetirizine dihydrochloride and montelukast Synergistic combination Formulation architecture & excipient selection Formulation development begins with analysis of the physical and chemical incompatibilities of the active ingredients with chosen excipients. Since the active components must be distributed evenly throughout the tablet, active ingredients with differing strengths require the blending process to be carefully fine-tuned.
In addition, the use of super disintegrants is especially important in dispersible tablets because they encourage rapid disintegration of the tablets when the appropriate liquid is used. To improve the integrity of the tablet, binders may be used as may lubricants and glidants for processing improvements. Flavoring and sweetening agents may also be incorporated. The pre formulation can then evaluate powder flow, cohesiveness, and moisture properties, and compatibility of active components and excipients.
The key composition can then be developed to optimize these factors so that the manufacturing of the pharmaceutical is reliable.
Active Ingredient Processing Accurate weighing of active components – such as levocetirizine dihydrochloride and montelukast – should be followed by constituent identity testing against approved specifications. Techniques such as sieving of active components (including the use of particle sizes) can be useful in assessing flowability and segregation tendencies. The individual components can then be processed via blending with excipients, with the active component distribution maintained using techniques like dilution or using established mixing parameters.
The blend is then tested for uniformity of distribution of the active components with particles of the same size distribution. Depending on the manufacturing process chosen, the blend can then be compressed or granulated prior to compression, with granule characteristics such as particle size distribution and moisture content assessed. Dispersible Tablet Processing and Control The compression process is optimized to give a durable tablet with fast dispersion.
The ability of the finished tablet to disperse is then tested to specification. Friability testing may also be performed, and physical examination used to identify cracking, chips, and surface defects. Optimization of processing parameters is continued until the tablet gives the specified durability and dispersing qualities. Stability of levocetirizine dihydrochloride 2.5MG + montelukast 5MG Dispersible Tablets Placebo blending – including particle size distribution and moisture content – can be monitored throughout the process and the finished product can be tested to establish stability under defined storage conditions.
Appearance, assay, and breakdown-related characteristics can be tracked at regular intervals.
Depending on the stability profile, appropriate packaging and moisture-protective methods can be incorporated. Quality Control and release testing The finished product can be tested to ensure it conforms to the approved specifications. Identity and assay of both active ingredients can be done by validated techniques.
Testing for uniformity of dosage units can be performed in accordance with recommended methods. Dispersible tablets can be evaluated for weight and weight variation, hardness, friability, dispersibility, and appearance. Additional testing, such as for dissolution, should measure performance.
Stability studies are performed to assess the product quality during storage. This can include testing of physical appearance, assay, active components' breakdown characteristics, and dispersion at specified time points. Moisture levels in the finished tablet can also be evaluated to identify moisture-related stability problems. Packaging and Integration into PCD Pharma Product Line Packaging is essential to maintain product quality and stability.
The final product can be packaged in blister packs or other suitable systems that will offer the desired protection against moisture and physical damage.
The packaging itself can be tested for materials compatibility and integrity of seals to ensure that product quality is maintained. The final product can then be labeled with batch information, storage requirements, contents, and other relevant data. The formula can be integrated into the company's product distribution, considering the potential range of growth of a PCD Pharma Franchise formulation range.
Levocetirizine Dihydrochloride 2.5MG + Montelukast 5MG Dispersible Tablets with formulation, manufacturing, quality, stability and packaging details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech